REFERENCES
- Cabral
BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Dis Mon.
2020 Aug;66(8):101015. doi: 10.1016/j.disamonth.2020.101015.
- Khan Z, Karataş Y, Kıroğlu O. Evaluation of Adverse Drug Reactions in
Paediatric Patients: A Retrospective Study in Turkish Hospital. Front
Pharmacol. 2021;12:786182. doi: 10.3389/fphar.2021.786182.
- Papakonstantinou
C, Papanastasiou K, Kotsopoulou M, Mouratidou M, Sotiropoulos D,
Kyrtsoni MC, Pouli A, Stamatelou M, Maniatis A. Chemotherapy-related
acute rhabdomyolysis. J Natl Cancer Inst. 1992 Apr 1;84(7):536-7.
- Levy RJ, Sparano JA, Khan G. Rhabdomyolysis: an unusual complication
of cytotoxic chemotherapy. Med Oncol. 1995 Dec;12(4):219-22. doi:
10.1007/BF02990567.
- Anderlini
P, Buzaid AC, Legha SS. Acute rhabdomyolysis after concurrent
administration of interleukin-2, interferon-alfa, and chemotherapy for
metastatic melanoma. Cancer. 1995 Aug 15;76(4):678-9. doi:
10.1002/1097-0142(19950815)76:4<678::aid-cncr2820760422>3.0.co;2-q.
- Hoshi S, Itoh A, Kato S, Suzuki K, Kawamura S, Orikasa S. Severe
rhabdomyolysis as a complication of high-dose chemotherapy in a
patient with advanced testicular cancer. Int J Urol. 1999
Jan;6(1):56-8. doi: 10.1046/j.1442-2042.1999.06130.x.
- Shima E, Hino M, Yamane T, Aoyama Y, Nakamae H, Yamamura R, Makita K,
Sugano Y, Yasuda S, Takubo T, Ohta K, Tatsumi N. Acute rhabdomyolysis
following administration of high-dose cyclophosphamide: case report.
Ann Hematol. 2002 Jan;81(1):55-6. doi: 10.1007/s00277-001-0399-2.
- Truica, C. I., & Frankel, S. R. (2002). Acute rhabdomyolysis as a
complication of cytarabine chemotherapy for acute myeloid leukemia:
case report and review of literature. Am J Hematol , 70,
320-323. doi: 10.1002/ajh.10152
- Truica CI, Frankel SR. Acute rhabdomyolysis as a complication of
cytarabine chemotherapy for acute myeloid leukemia: case report and
review of literature. Am J Hematol. 2002 Aug;70(4):320-3. doi:
10.1002/ajh.10152.
- Ceribelli A, Cecere FL, Milella M, Facciolo F, Gelibter A, Cognetti F.
Severe rhabdomyolysis associated with pemetrexed-based chemotherapy.
Lancet Oncol. 2006 Apr;7(4):353. doi: 10.1016/S1470-2045(06)70662-3.
- Ramamoorthy
SK, Marangolo M, Durrant E, Akima S, Gottlieb DJ. Unusual reaction to
Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure
and bone marrow necrosis. Leuk Lymphoma. 2006 Apr;47(4):747-50.
- Penel
N, Blay JY, Adenis A. Imatinib as a possible cause of severe
rhabdomyolysis. N Engl J Med. 2008 Jun 19;358(25):2746-7. doi:
10.1056/NEJMc0708896.
- Veeraputhiran
M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic
interaction between erlotinib and simvastatin. Clin Lung Cancer. 2008
Jul;9(4):232-4. doi: 10.3816/CLC.2008.n.036.
- Vicente E, Zafra M, Garcia-Martinez E, de la Peña FA. Acute
rhabdomyolysis as a complication of paclitaxel-gemcitabine
chemotherapy for ovarian cancer. Eur J Obstet Gynecol Reprod Biol.
2009 Aug;145(2):226. doi: 10.1016/j.ejogrb.2009.04.029.
- Urata C, Yoshimura M, Itamura H, Hisatomi T, Kubota Y, Fukushima N,
Sueoka E, Kimura S. Lenalidomide in combination with dexamethasone
induced rhabdomyolysis in a multiple myeloma patient treated with
pravastatin. Int J Hematol. 2011 Aug;94(2):216-217. doi:
10.1007/s12185-011-0903-y.
- Moscetti L, Nelli F, Ruggeri EM. Rhabdomyolysis from erlotinib: a case
report. Tumori. 2011 May-Jun;97(3):415-6. doi: 10.1700/912.10044.
- Huang
MS, Tsai JR, Shen MC, Chou SH, Yang CJ. Pemetrexed as a possible cause
of severe rhabdomyolysis in the treatment of lung cancer. Lung Cancer.
2012 Jun;76(3):491-2. doi: 10.1016/j.lungcan.2012.02.009.
- Sobol
G, Musioł K, Mizia-Malarz A, Stolpa W, Krupa M, Woś H. Rhabdomyolysis:
rare complications with a difficult prognosis in the course of
anticancer treatment. J Pediatr Hematol Oncol. 2012 May;34(4):e142-4.
doi: 10.1097/MPH.0b013e318236b2fd.
- Matsuzaki H, Koga Y, Suminoe A, Oba U, Takimoto T, Hara T. Severe
acute rhabdomyolysis induced by multi-agent chemotherapy for alveolar
rhabdomyosarcoma in a 15-year-old female: a case report. Case Rep
Oncol. 2013 Jul 31;6(2):397-402. doi: 10.1159/000354271.
- Gavigan G, McEvoy A, Young V. Acute rhabdomyolysis as a complication
of interferon treatment for stage IIIc melanoma. J Cutan Med Surg.
2014 Jul-Aug;18(4):277-9. doi: 10.2310/7750.2013.13115.
- Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma:
durable tumor response associated with severe hypothyroidism and
rhabdomyolysis. Cancer Immunol Res. 2014 Jan;2(1):15-8. doi:
10.1158/2326-6066.CIR-13-0146.
- Hong
YA, Kim HD, Jo K, Park YK, Lee J, Sun IO, Chung BH, Park CW, Yang CW,
Choi BS. Severe rhabdomyolysis associated with concurrent use of
simvastatin and sirolimus after cisplatin-based chemotherapy in a
kidney transplant recipient. Exp Clin Transplant. 2014
Apr;12(2):152-5. doi: 10.6002/ect.2013.0003.
- Koršić M, Muršić D, Badovinac S, Božina N, Roglić M, Jakopović M,
Čučević B. Erlotinib-related rhabdomyolysis: the role of
pharmacogenetics and drug-drug interaction. Cancer Chemother
Pharmacol. 2015 Dec;76(6):1317-9. doi: 10.1007/s00280-015-2885-6.
- Neyra JA, Rocha NA, Bhargava R, Vaidya OU, Hendricks AR, Rodan AR.
Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed
to denosumab and abiraterone: a case report. BMC Nephrol. 2015 Jul
30;16:118. doi: 10.1186/s12882-015-0113-6.
- Sakai K, Mochizuki H, Mochida K, Shiomi K, Amano M, Nakazato M. A Case
of Nivolumab-Induced Severe Mononeuropathy Multiplex and
Rhabdomyolysis. Case Rep Med. 2017;2017:1093858. doi:
10.1155/2017/1093858.
- He
H, An R, Hou J, Fu W. Arsenic trioxide induced rhabdomyolysis, a rare
but severe side effect, in an APL patient: a case report. Front Med.
2017 Jun;11(2):284-286. doi: 10.1007/s11684-017-0514-y.
- Sokolova A, Chan O, Ullah W, Hamdani AA, Anwer F. Delayed
rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide
regimen: a case report. J Med Case Rep. 2017 Apr 11;11(1):100. doi:
10.1186/s13256-017-1272-9.
- Logue
JM, Kiani B, Bitting RL. Pazopanib and Statin-Induced Rhabdomyolysis.
Case Rep Oncol. 2017 Oct 31;10(3):954-957. doi: 10.1159/000481659.
- Hamada S, Fuseya Y, Tsukino M. Pembrolizumab-Induced Rhabdomyolysis
With Myositis in a Patient With Lung Adenocarcinoma. Arch Bronconeumol
(Engl Ed). 2018 Jun;54(6):346-348. English, Spanish. doi:
10.1016/j.arbres.2018.01.026.
- Damato A, Larocca M, Rondini E, Menga M, Pinto C, Versari A. Severe
Rhabdomyolysis during Treatment with Trabectedin in Combination with a
Herbal Drug in a Patient with Metastatic Synovial Sarcoma: A Case
Report. Case Rep Oncol. 2017 Mar 28;10(1):258-264. doi:
10.1159/000464440.
- Chen
Q, Huang DS, Zhang LW, Li YQ, Wang HW, Liu HB. Fatal myocarditis and
rhabdomyolysis induced by nivolumab during the treatment of type B3
thymoma. Clin Toxicol (Phila). 2018 Jul;56(7):667-671. doi:
10.1080/15563650.2017.1401079.
- Sullivan K, Lee CS. Pemetrexed-induced severe rhabdomyolysis in lung
cancer: A case report. J Oncol Pharm Pract. 2019 Dec;25(8):2007-2009.
doi: 10.1177/1078155218816767.
- Clark
JI, Bufalino S, Singh S, Borys E. Rhabdomyolysis during high dose
interleukin-2 treatment of metastatic melanoma after sequential
immunotherapies: a case report. J Immunother Cancer. 2018 Jun
14;6(1):53. doi: 10.1186/s40425-018-0370-6.
- Dineen M, Hansen E, Guancial E, Sievert L, Sahasrabudhe D.
Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A
case report and review of the literature. J Oncol Pharm Pract. 2018
Jun;24(4):314-318. doi: 10.1177/1078155217701294.
- Muto
Y, Ng W, Namikawa K, Takahashi A, Tsutsumida A, Nishida M, Yamazaki N.
Success of rechallenging dabrafenib and trametinib combination therapy
after trametinib-induced rhabdomyolysis: a case report. Melanoma Res.
2018 Apr;28(2):151-154. doi: 10.1097/CMR.0000000000000424.
- Pourhassan HZ, Tryon D, Schaeffer B, Mirshahidi H, Wong J. Autoimmune
rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced
immune related adverse events during treatment of metastatic melanoma.
Exp Hematol Oncol. 2019 Sep 10;8:20. doi: 10.1186/s40164-019-0140-2.
- Irimada, M., Fujimura, T., Kambayashi, Y., Tsukada, A., Takahashi, T.,
Hashimoto, A.,… Aiba, S. (2019). Severe rhabdomyolysis developing in
an advanced melanoma patient treated by pembrolizumab followed by
dabrafenib trametinib combined therapy. J Dermatol , 46,
e256-e258. doi: 10.1111/1346-8138.14778
- Irimada M, Fujimura T, Kambayashi Y, Tsukada A, Takahashi T, Hashimoto
A, Aiba S. Severe rhabdomyolysis developing in an advanced melanoma
patient treated by pembrolizumab followed by dabrafenib trametinib
combined therapy. J Dermatol. 2019 Jul;46(7):e256-e258. doi:
10.1111/1346-8138.14778.
- Thalambedu N, Atiq MU, Patel S. A Case of Docetaxel-Induced
Rhabdomyolysis. Cureus. 2020 Jul 25;12(7):e9380. doi:
10.7759/cureus.9380.
- Díaz
Alcázar MDM, Cervilla Sáez de Tejada E, Ruiz Escolano E.
Rhabdomyolysis in a patient under treatment with sorafenib. Rev Esp
Enferm Dig. 2020 Mar;112(3):243-244. doi:
10.17235/reed.2020.6440/2019.
- Adachi Y, Yanagimura N, Suzuki C, Ootani S, Tanimoto A, Nishiyama A,
Yamashita K, Ohtsubo K, Takeuchi S, Yano S. Reduced doses of
dabrafenib and trametinib combination therapy for BRAF V600E-mutant
non-small cell lung cancer prevent rhabdomyolysis and maintain tumor
shrinkage: a case report. BMC Cancer. 2020 Feb 24;20(1):156. doi:
10.1186/s12885-020-6626-9.
- Finsterer
J. Trametinib and dabrafenib induced rhabdomyolysis, renal failure,
and visual loss. Report of one case. Rev Med Chil. 2020
Nov;148(11):1684-1689. doi: 10.4067/S0034-98872020001101684.
- Abushalha K, Abulaimoun S, Silberstein PT. So slow, so fast, a case of
nivolumab-induced hypothyroidism with subsequent rhabdomyolysis.
Immunotherapy. 2020 Jun;12(9):625-628. doi: 10.2217/imt-2020-0053.
- Ould-Nana I, Cillis M, Gizzi M, Gillion V, Hantson P, Gérard L.
Rhabdomyolysis and acute kidney injury induced by the association of
rosuvastatin and abiraterone: A case report and review of the
literature. J Oncol Pharm Pract. 2021 Jan;27(1):216-219. doi:
10.1177/1078155220923001.
- Khan
T, Gurav P. PhytoNanotechnology: Enhancing Delivery of Plant Based
Anti-cancer Drugs. Front Pharmacol. 2018 Feb 9;8:1002. doi:
10.3389/fphar.2017.01002.
- Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S, Yu L. The
Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.
Front Pharmacol. 2020 Mar 20;11:343. doi: 10.3389/fphar.2020.00343.
- Ge L, Li N, Yuan GW, Sun YC, Wu LY. Nedaplatin and paclitaxel compared
with carboplatin and paclitaxel for patients with platinum-sensitive
recurrent ovarian cancer. Am J Cancer Res. 2018 Jun 1;8(6):1074-1082.
- Wang H, Zhu X, Huang J, Chen P, Han S, Yan X. Nedaplatin sensitization
of cisplatin-resistant human non-small cell lung cancer cells. Oncol
Lett. 2016 Apr;11(4):2566-2572. doi: 10.3892/ol.2016.4276.
- Yang JJ, Zhou Q, Liao RQ, Huang YS, Xu CR, Wang Z, Wang BC, Chen HJ,
Wu YL. Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in
Treatment of Advanced Non-small Cell Lung Cancer: A Randomized
Clinical Trial. Chin J Cancer Res. 2012 Jun;24(2):97-102. doi:
10.1007/s11670-012-0097-8.
- Zhang K, Qin H, Pan F, Liu E, Liang H, Ruan Z. Nedaplatin or
oxaliplatin combined with paclitaxel and docetaxel as first-line
treatment for patients with advanced non-small cell lung cancer. Med
Sci Monit. 2014 Dec 30;20:2830-6. doi: 10.12659/MSM.891318.
- Kawarada Y, Miyazaki M, Itoh A, Araki R, Iwamizu H, Kataoka T,
Kumakura Y, Ota A, Nagai T, Yamada K. Incidence of and risk factors
associated with nedaplatin-related hypersensitivity reactions. Int J
Clin Oncol. 2017 Jun;22(3):593-599. doi: 10.1007/s10147-017-1091-4.